Last $1.34 USD
Change Today 0.00 / 0.00%
Volume 0.0
PRPH On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

prophase labs inc (PRPH) Snapshot

Open
$1.31
Previous Close
$1.30
Day High
$1.37
Day Low
$1.28
52 Week High
05/13/14 - $2.23
52 Week Low
10/8/14 - $1.21
Market Cap
20.7M
Average Volume 10 Days
15.0K
EPS TTM
$-0.18
Shares Outstanding
15.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROPHASE LABS INC (PRPH)

Related News

No related news articles were found.

prophase labs inc (PRPH) Related Businessweek News

No Related Businessweek News Found

prophase labs inc (PRPH) Details

ProPhase Labs, Inc. engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public. It is also involved in the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care, and cosmeceutical products. The company offers Cold-EEZE, a zinc gluconate lozenge to reduce the duration and severity of the common cold symptoms. It also markets and distributes non-lozenge forms of its proprietary zinc gluconate formulation, Cold-EEZE daytime/nighttime QuickMelts and Cold-EEZE oral spray; and Kids-EEZE products, as well as Organix Rx Complete, an organic cough/cold drop and Organix Rx Defense, a Vitamin C supplement drop. It also provides private label lozenge products for retail customers; and performs contract manufacturing services of cough drop and other OTC cold remedy products for third parties. ProPhase Labs, Inc. sells its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.

50 Employees
Last Reported Date: 03/27/14
Founded in 1989

prophase labs inc (PRPH) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $775.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

prophase labs inc (PRPH) Key Developments

ProPhase Labs, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

ProPhase Labs, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $5,130,000 compared to $5,949,000 a year ago. Loss from operations was $3,215,000 compared to income from operations of $1,239,000 a year ago. Loss before income tax was $3,216,000 compared to income before income tax of $1,236,000 a year ago. Net loss was $3,216,000 or $0.18 per basic and diluted share compared to net income of $1,236,000 or $0.08 per basic and diluted share a year ago. Results for the third quarter of 2014 compared to the third quarter of 2013 principally reflect the net effect of a decrease in net sales of $819,000 principally due to a decline in contract manufacturing sales of $566,000, an increase in research and development costs of $175,000, an increase of $611,000 in administration costs due principally to an increase in legal and professional costs relating to litigation expenses arising from prior pending litigation, the Impairment Charge of $3.6 million, offset by a decrease in sales and marketing expenses of $216,000. For the nine months, the company reported net sales of $13,098,000 compared to $15,430,000 a year ago. Loss from operations was $7,154,000 compared to $186,000 a year ago. Loss before income tax was $7,158,000 compared to $193,000 a year ago. Net loss was $7,158,000 or $0.42 per basic and diluted share compared to $193,000 or $0.01 per basic and diluted share a year ago. The financial results for the nine months ended September 30, 2014 as compared to nine months ended September 30, 2013 reflect the net effect of a decrease of revenues due principally to: industry data suggesting there was reduction in the incidence of upper respiratory disorders from period to period and, as a consequence, the timing of purchases and the ultimate level of demand for products, and a decrease of approximately $700,000 in contract manufacturing sales, and an increase of $1.7 million in administration costs due principally to an increase in legal and professional costs principally relating to now resolved litigation matters, an increase in research and development expenditures of $321,000 as the company seeks to expand future product offerings to consumers, the Impairment Charge of $3.6 million, offset by a decrease in sales and marketing expenses of $439,000 as a consequence of the fluctuation from period to period of the timing and scope of marketing initiatives.

ProPhase Labs, Inc. Finalizes Resolution of Long-Standing Litigations

ProPhase Labs, Inc. announced the company has consummated a definitive, global Settlement Agreement resolving all of its litigation with certain of the company's former managers and with certain shareholders. The cases that have been settled include ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2010-08227; ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2011-09815; the appeal filed by the plaintiff in the matter Quigley v. ProPhase Labs. Inc.'s Officers and Directors, el al, Court of Common Pleas of Philadelphia County, December Term, 2011, No. 111200409; together with certain ancillary litigation. Terms of the Settlement: The Settlement Agreement resolving these matters provides in part that the parties adverse to the Company in the two Bucks County cases will: return to the company up to 3,896,764 shares of the company's common stock for which they are listed as the record owners to the company; and remit $440,000 to the company. The Settlement Agreement also provides that the company, in turn, will fund, or will deduct from the exercise price to be paid if the option is exercised, up to $500,000 for the benefit of one of the defendants, to defray certain costs and expenses associated with the transactions concerning the Option Shares. Pursuant to the Settlement Agreement, the parties also have agreed to a mutual release of all claims, a standstill agreement whereby, for a period of ten years, the adverse parties will not acquire company shares, and the dismissal of all pending litigation involving the company, its directors and affiliates on the one hand, and the other parties.

ProPhase Labs, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ProPhase Labs, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, net sales were $1.8 million as compared to net sales of $1.9 million for the three months ended June 30, 2013. The company realized a net loss of $3.1 million, or $0.19 per share, compared to a net loss of $1.7 million, or $0.11 per share, for the three months ended June 30, 2013. The company's sales are derived principally from its over-the-counter cold remedy products. Loss from operations was $3.14 million compared to $1.72 million a year ago. Loss before income tax was $3.14 million compared to $1.72 million a year ago. For the six months, the company generated net sales of $8.0 million, as compared to $9.5 million for the six months ended June 30, 2013. The company incurred a net loss of $3.9 million, or $0.24 per share, compared to a net loss of $1.4 million, or $0.09 per share, for the six months ended June 30, 2013. Loss from operations was $3.94 million compared to $1.43 million a year ago. Loss before income tax was $3.94 million compared to $1.43 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRPH:US $1.34 USD 0.00

PRPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $50.88 USD 0.00
Momenta Pharmaceuticals Inc $14.67 USD 0.00
Pernix Therapeutics Holdings Inc $11.50 USD 0.00
Sagent Pharmaceuticals Inc $27.40 USD 0.00
Salix Pharmaceuticals Ltd $157.44 USD 0.00
View Industry Companies
 

Industry Analysis

PRPH

Industry Average

Valuation PRPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROPHASE LABS INC, please visit www.prophaselabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.